COVID-19 Associated Coagulopathy and Implications for its Treatment

The SARS-CoV-2 coronavirus (COVID-19) pandemic is due to lack of prior immunity and there is no certain management, regarding the complications of this viral illness. The target organ for COVID-19 infection are the lungs. Patients may develop acute lung injury that can be complicated by acute respir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cherneva Zh., Cherneva R.
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2020
Materias:	coagulopathy coronavirus covid-19 anticoagulation sepsis Medicine R
Acceso en línea:	https://doaj.org/article/568b7f711ad346d6bbaee40ca12a0804
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:568b7f711ad346d6bbaee40ca12a0804
record_format	dspace
spelling	oai:doaj.org-article:568b7f711ad346d6bbaee40ca12a08042021-12-02T17:31:30ZCOVID-19 Associated Coagulopathy and Implications for its Treatment0324-175010.2478/amb-2020-0035https://doaj.org/article/568b7f711ad346d6bbaee40ca12a08042020-09-01T00:00:00Zhttps://doi.org/10.2478/amb-2020-0035https://doaj.org/toc/0324-1750The SARS-CoV-2 coronavirus (COVID-19) pandemic is due to lack of prior immunity and there is no certain management, regarding the complications of this viral illness. The target organ for COVID-19 infection are the lungs. Patients may develop acute lung injury that can be complicated by acute respiratory failure, as well as multiorgan failure. The pathophysiology of COVID-19 infection is characterized with inflammatory changes, associated with coagulopathy. Recent data suggests diffuse bilateral pulmonary inflammation observed in COVID-19 infection that is related to a novel pulmonary-specific vasculopathy, defined as pulmonary intravascular coagulopathy (PIC), distinct from disseminated intravascular coagulopathy (DIC). The coagulopathy associated with COVID-19 is distinguished by initial elevation of D-dimer and fibrin/fibrinogen degradation products. Abnormalities in prothrombin time (PT), partial thromboplastin time (APTT) and platelet counts are not common in the early stages of the infection. This suggests the early screening measurement of D-dimer and fibrinogen. The implications for COVID-19-associated-coagulopathy is the established thromboembolic prophylaxis and standard management for sepsis-induced coagulopathy or DIC. High levels of D-dimer are a marker of higher mortality risk. However, current studies do not show the common use of full therapeutical doses of anticoagulants, unless there are other clinical indications. Bleeding in COVID-19 infection is uncommon, even when a laboratory constellation for DIC is present. However, if it occurs, standard guidelines for DIC management should be followed.Cherneva Zh.Cherneva R.Sciendoarticlecoagulopathycoronaviruscovid-19anticoagulationsepsisMedicineRENActa Medica Bulgarica, Vol 47, Iss 3, Pp 48-52 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	coagulopathy coronavirus covid-19 anticoagulation sepsis Medicine R
spellingShingle	coagulopathy coronavirus covid-19 anticoagulation sepsis Medicine R Cherneva Zh. Cherneva R. COVID-19 Associated Coagulopathy and Implications for its Treatment
description	The SARS-CoV-2 coronavirus (COVID-19) pandemic is due to lack of prior immunity and there is no certain management, regarding the complications of this viral illness. The target organ for COVID-19 infection are the lungs. Patients may develop acute lung injury that can be complicated by acute respiratory failure, as well as multiorgan failure. The pathophysiology of COVID-19 infection is characterized with inflammatory changes, associated with coagulopathy. Recent data suggests diffuse bilateral pulmonary inflammation observed in COVID-19 infection that is related to a novel pulmonary-specific vasculopathy, defined as pulmonary intravascular coagulopathy (PIC), distinct from disseminated intravascular coagulopathy (DIC). The coagulopathy associated with COVID-19 is distinguished by initial elevation of D-dimer and fibrin/fibrinogen degradation products. Abnormalities in prothrombin time (PT), partial thromboplastin time (APTT) and platelet counts are not common in the early stages of the infection. This suggests the early screening measurement of D-dimer and fibrinogen. The implications for COVID-19-associated-coagulopathy is the established thromboembolic prophylaxis and standard management for sepsis-induced coagulopathy or DIC. High levels of D-dimer are a marker of higher mortality risk. However, current studies do not show the common use of full therapeutical doses of anticoagulants, unless there are other clinical indications. Bleeding in COVID-19 infection is uncommon, even when a laboratory constellation for DIC is present. However, if it occurs, standard guidelines for DIC management should be followed.
format	article
author	Cherneva Zh. Cherneva R.
author_facet	Cherneva Zh. Cherneva R.
author_sort	Cherneva Zh.
title	COVID-19 Associated Coagulopathy and Implications for its Treatment
title_short	COVID-19 Associated Coagulopathy and Implications for its Treatment
title_full	COVID-19 Associated Coagulopathy and Implications for its Treatment
title_fullStr	COVID-19 Associated Coagulopathy and Implications for its Treatment
title_full_unstemmed	COVID-19 Associated Coagulopathy and Implications for its Treatment
title_sort	covid-19 associated coagulopathy and implications for its treatment
publisher	Sciendo
publishDate	2020
url	https://doaj.org/article/568b7f711ad346d6bbaee40ca12a0804
work_keys_str_mv	AT chernevazh covid19associatedcoagulopathyandimplicationsforitstreatment AT chernevar covid19associatedcoagulopathyandimplicationsforitstreatment
_version_	1718380553117368320

COVID-19 Associated Coagulopathy and Implications for its Treatment

Ejemplares similares